Quality of life and tamoxifen in a breast cancer prevention trial: A summary of findings from the NSABP P-1 study

Annals of the New York Academy of Sciences

Volumn 949, Issue , 2001, Pages 143-150

  Day, Richard ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Breast cancer; Prevention; Quality of life; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; BREAST CANCER; CANCER PREVENTION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MENTAL HEALTH; PHASE 1 CLINICAL TRIAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SEXUAL FUNCTION; VAGINA DISCHARGE; WEIGHT GAIN;

EID: 0035680437     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb04012.x     Document Type: Conference Paper

References (15)

1. Tamoxifen for the prevention of breast cancer: A report from the NSABP P-1 study
2. Highlights of the NSABP breast cancer prevention trial
3. Baseline quality-of-life assessment in the national surgical adjuvant breast and bowel project breast cancer prevention trial
4. Compliance with quality of life data collection in the NSABP breast cancer prevention trial
5. Health-related quality of life and tamoxifen in breast cancer prevention: A report from the NSABP P-1 study
6. The CES-D scale: A self-report depression scale for research in the general population
7. The center for epidemiologic studies depression scale: Its use in a community sample
8. Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen
9. Symptoms associated with tamoxifen treatment in postmenopausal women
10. Mood disorder in women with early breast cancer taking tamoxifen, an estradiol receptor antagonist: An unexpected effect?
11. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients
12. Reversible central nervous system dysfunction due to tamoxifen in a patient with breast cancer
13. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
14. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors